These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 2431427)
1. CSF levels of receptor-active endorphins in schizophrenic patients: correlations with symptomatology and monoamine metabolites. Lindström LH; Besev G; Gunne LM; Terenius L Psychiatry Res; 1986 Oct; 19(2):93-100. PubMed ID: 2431427 [TBL] [Abstract][Full Text] [Related]
2. Monoamine neurotransmitter interactions in drug-free and neuroleptic-treated schizophrenics. Hsiao JK; Colison J; Bartko JJ; Doran AR; Konicki PE; Potter WZ; Pickar D Arch Gen Psychiatry; 1993 Aug; 50(8):606-14. PubMed ID: 7688209 [TBL] [Abstract][Full Text] [Related]
3. Low HVA and normal 5HIAA CSF levels in drug-free schizophrenic patients compared to healthy volunteers: correlations to symptomatology and family history. Lindström LH Psychiatry Res; 1985 Apr; 14(4):265-73. PubMed ID: 2410940 [TBL] [Abstract][Full Text] [Related]
4. Effect of neuroleptic medication on cerebrospinal fluid monoamine metabolite concentrations in schizophrenia. Serotonin-dopamine interactions as a target for treatment. Kahn RS; Davidson M; Knott P; Stern RG; Apter S; Davis KL Arch Gen Psychiatry; 1993 Aug; 50(8):599-605. PubMed ID: 7688208 [TBL] [Abstract][Full Text] [Related]
5. CSF levels of HVA and 5-HIAA in drug-free schizophrenic patients and healthy controls: a prospective study focused on their predictive value for outcome in schizophrenia. Wieselgren IM; Lindström LH Psychiatry Res; 1998 Nov; 81(2):101-10. PubMed ID: 9858027 [TBL] [Abstract][Full Text] [Related]
6. CSF concentrations of neurotensin in schizophrenia: an investigation of clinical and biochemical correlates. Breslin NA; Suddath RL; Bissette G; Nemeroff CB; Lowrimore P; Weinberger DR Schizophr Res; 1994 Apr; 12(1):35-41. PubMed ID: 7517175 [TBL] [Abstract][Full Text] [Related]
7. Concentrations of monoamine metabolites and chlorpromazine in cerebrospinal fluid for prediction of therapeutic response in psychotic patients treated with neuroleptic drugs. Sedvall G Prog Biochem Pharmacol; 1980; 16():133-40. PubMed ID: 6160594 [TBL] [Abstract][Full Text] [Related]
8. The dopamine-serotonin relationship in clozapine response. Szymanski S; Lieberman J; Pollack S; Munne R; Safferman A; Kane J; Kronig M; Cooper T Psychopharmacology (Berl); 1993; 112(1 Suppl):S85-9. PubMed ID: 7530378 [TBL] [Abstract][Full Text] [Related]
9. Decrease in dopamine, its metabolites and noradrenaline in cerebrospinal fluid of schizophrenic patients after withdrawal of long-term neuroleptic treatment. Bagdy G; Perényi A; Frecska E; Révai K; Papp Z; Fekete MI; Arató M Psychopharmacology (Berl); 1985; 85(1):62-4. PubMed ID: 2580329 [TBL] [Abstract][Full Text] [Related]
10. Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis. Implications for regional brain dysfunction in schizophrenia. Pickar D; Breier A; Hsiao JK; Doran AR; Wolkowitz OM; Pato CN; Konicki PE; Potter WZ Arch Gen Psychiatry; 1990 Jul; 47(7):641-8. PubMed ID: 1694425 [TBL] [Abstract][Full Text] [Related]
11. The effect of olanzapine treatment on monoamine metabolite concentrations in the cerebrospinal fluid of schizophrenic patients. Scheepers FE; Gispen-de Wied CC; Westenberg HG; Kahn RS Neuropsychopharmacology; 2001 Oct; 25(4):468-75. PubMed ID: 11557160 [TBL] [Abstract][Full Text] [Related]
12. CSF monoamine metabolites in chronic schizophrenic patients who attempt suicide. Roy A; Ninan P; Mazonson A; Pickar D; Van Kammen D; Linnoila M; Paul SM Psychol Med; 1985 May; 15(2):335-40. PubMed ID: 2410941 [TBL] [Abstract][Full Text] [Related]
13. [Changes in the CSF levels of monoamine metabolites in 102 chronic schizophrenic patients following probenecid before and after neuroleptic medication]. Chen YF Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1984 Oct; 17(5):273-7. PubMed ID: 6085683 [No Abstract] [Full Text] [Related]
14. Relationship between abnormal brainstem auditory-evoked potentials and subnormal CSF levels of HVA and 5-HIAA in first-episode schizophrenic patients. Lindström LH; Wieselgren IM; Klockhoff I; Svedberg A Biol Psychiatry; 1990 Sep; 28(5):435-42. PubMed ID: 1698468 [TBL] [Abstract][Full Text] [Related]
15. Monoamine metabolite levels in cerebrospinal fluid and brain atrophy in lobotomized schizophrenic patients. Rimón R; Roos BE; Kampman R; Hyyppä S; Ranta P; Myllylä V Ann Clin Res; 1979 Feb; 11(1):25-9. PubMed ID: 453776 [TBL] [Abstract][Full Text] [Related]
16. Aberrant monoamine metabolite levels in CSF and family history of schizophrenia. Their relationships in schizophrenic patients. Sedvall GC; Wode-Helgodt B Arch Gen Psychiatry; 1980 Oct; 37(10):1113-6. PubMed ID: 6158928 [TBL] [Abstract][Full Text] [Related]
18. The relationship between clinical and biochemical changes following neuroleptic treatment in schizophrenia. Cooper SJ; Leahey W; Liddle J; King DJ Schizophr Res; 1990; 3(4):261-7. PubMed ID: 1703780 [TBL] [Abstract][Full Text] [Related]